No, Watson appeal has nothing to do with the FDA leaving Amarin exclusivity as "No expired exclusivity". IMO Amarin will not be assigned exclusivity until after REDUCE-IT. If the exclusivity committee could agree on NCE for Marine it would have happened. For the FDA they want the results of REDUCE-IT. NME wasn't an exceptable Regulatory scheme according to Judge Moss. "No expired exclusivity" can be left until FDA has the information to make an appropriate decision.
Market Data 
Markets 
AI
